Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?

To: ithasnospaces who wrote (432)	3/10/1998 11:03:00 PM
From: Mason Barge	Respond to of 696

<<BIOI has a price-to-book ratio of 1.8 - less than the industry average of 3.6>> I've got to say (as a BIOI investor) that this is a somewhat misleading comparison. Most of the biotech industry has very high PB and PS ratios on expectation of future sales. BIOI is a supplier and doesn't really belong in the biotech sector, except that its sales are tied to the sector because the more money that comes into biotech, the more BIOI makes. Even so, a PB of 1.8 is reasonable IF the company has growth prospects. I keep hearing cheerleading about growth, but . . . well, where the hell is it?